(Originally posted 7/29/22; updated 8/5/22)
Summary
Second quarter 2022 company financial reports for smid-cap biopharma companies began at the beginning of August
Many of these companies will report revenue from approved products
These reports can also be important for companies with readouts expected in Q3 2022 as data may be announced in the quarterly report
See our free public Google Sheet with info on report times and subscribe to see our full Google Sheet including approved products and Q3 readouts
Now updated for reports from 8/15-8/19
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
Quarterly company reports are ramping up next week, especially for smid-cap biopharma companies. Beginning on Monday (August 1), almost 100 companies in the BPIQ database will be reporting Q2 financial reports. In 2021, about one third of the BPIQ companies reported Q2 results in the first week of August and almost 75% of companies presented Q2 results within the first two weeks of August. Thus, these next two weeks are a very important time for smid-cap biopharmas.
Many of these companies have lead products that are approved, and so quarterly reports can influence stock price as they give good insight into how revenue has changed over the past several quarters. We track previous quarters revenue of these products at BPIQ in our IQ cards for our BPIQ and Amp subscribers. We also monitor those companies with readouts before September to see if dates have changed with quarterly reports, or if they report any readout data.
BPIQ has compiled the dates and times of these smid-cap biopharma company reports happening next week. See our free public Google Sheet for this information.
For much more info on companies reporting out next week, become a BPIQ or Amp subscriber (special intro rates) today (CLICK HERE). BPIQ and Amp subscribers see our ENHANCED Google Sheet: For example, learn about which of these companies have Q3 readouts, are reporting revenue of approved products, and which of those approved products were approved since Jan 2021, and thus whose revenue is more likely particularly impactful.
Come back every Friday to see the updated list of upcoming reports.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history: 7/29/22 initially published post
Updated 8/12/22
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
P.S. We are currently running a sale - lock in the price before it's gone
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comentarios